Welcome to our dedicated page for Biotricity news (Ticker: BTCY), a resource for investors and traders seeking the latest updates and insights on Biotricity stock.
Biotricity, Inc. (BTCY) is a medical technology company at the forefront of healthcare innovation. Specializing in biometric data monitoring solutions, Biotricity aims to improve healthcare by developing remote monitoring solutions for chronic disease prevention and management. Its premier product, Bioflux, is an ECG monitoring system used by physicians to diagnose and monitor cardiac patients remotely. Biotricity's Biolife solution extends medical-grade monitoring to the consumer market, empowering users to self-manage chronic conditions through lifestyle changes. With a focus on preventive healthcare, Biotricity's R&D efforts aim to put health management directly into the hands of individuals, easing the burden on the healthcare system.
Rhea-AI Summary
Biotricity Inc. (Nasdaq:BTCY) reports a 21.4% YOY revenue increase in Q2-FY24 to $2.9 million, with significant improvements in gross margins and a 22% reduction in SG&A. Recurring technology fees, customer device sales, continue to trend upwards, and net loss decreases by 21%. The company's CEO highlights the success of its Bioflux and Biotres products in monitoring atrial fibrillation and introduces AI-driven solutions to redefine medical diagnostics and patient care. The Q2-FY24 Financial Highlights and Operating Highlights demonstrate substantial growth and expansion in the company's services and products.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Biotricity Inc. (Nasdaq:BTCY) announces improved margins, reduced selling expenses, and lower operating losses. The company will host its Second Quarter Fiscal Year 2024 Financial Results and Business Update Call on November 14, 2023. Investors can access the webcast and a replay via the Biotricity website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.11%
Tags
-
Rhea-AI Summary
Biotricity Inc. announces the expansion of its Biotres product platform with the introduction of Biotres Pro, which includes cellular backup for offline connectivity. The company has also filed a patent application for its cutting-edge 3 channel technology. With the addition of Biotres Pro, Biotricity now has the most comprehensive remote cardiac monitoring portfolio in the market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.68%
Tags
Rhea-AI Summary
Biotricity files patent for Bioheart device, a wearable heart monitoring solution. The patent safeguards Bioheart's technology, design, and form factor.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.42%
Tags
-
Rhea-AI Summary
Biotricity files patent application for Biotres device, expanding IP portfolio and increasing market barriers. CEO plans to file two additional patents within the next year. Biotres device offers continuous, real-time data on vital signs and redefines cardiac monitoring. It reduces results wait time from 2 weeks to 3 days or less.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.93%
Tags
-
Rhea-AI Summary
Biotricity files patent application for Biotres device, expanding IP portfolio and increasing market barriers. CEO plans to file two additional patents within the next year. Biotres offers continuous real-time data on vital signs and redefines cardiac monitoring. Available for purchase on www.biotricity.com.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.47%
Tags
Rhea-AI Summary
Biotricity launches new digital presence showcasing their healthcare technologies and solutions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.37%
Tags
-
Rhea-AI Summary
Biotricity achieves record $14 million annualized revenue run rate, showing over 8% growth. Better patient outcomes and substantial cost savings reported in Corporate Impact Report.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.42%
Tags
-
Rhea-AI Summary
Biotricity Inc. reports Q1-FY24 revenue growth of 46.9% YoY to $3.0 million. Recurring technology fees and customer device sales continue to trend higher. Gross margins improve to 63.5% from 59.6% in the same period last year. Net loss improved by 28% to $3.6 million. The company aims to increase sales, ramp up subscription-based service, accelerate recurring revenue, and draw a clear path to profitability.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.83%
Tags
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.02%
Tags
FAQ
What is the current stock price of Biotricity (BTCY)?
The current stock price of Biotricity (BTCY) is $0.645 as of February 21, 2025.
What is the market cap of Biotricity (BTCY)?
The market cap of Biotricity (BTCY) is approximately 14.3M.
What is Biotricity, Inc.?
Biotricity, Inc. is a medical technology company focused on developing biometric data monitoring solutions for chronic disease prevention and management.
What are some of Biotricity's products?
Biotricity's premier product is Bioflux, an ECG monitoring system used for diagnosing and remotely monitoring cardiac patients. The company also offers Biolife, a consumer-focused solution for self-managing chronic conditions.
What is the vision of Biotricity, Inc.?
Biotricity aims to empower individuals by providing innovative solutions for preventive healthcare, ultimately enabling users to take control of their health and manage critical conditions effectively.
How does Biotricity contribute to the healthcare industry?
Biotricity's focus on remote monitoring and chronic care management bridges the gap in healthcare services, offering diagnostic and post-diagnostic solutions for chronic conditions, particularly in the cardiology sector.
Biotricity Inc
Nasdaq:BTCY
BTCY Rankings
BTCY Stock Data
14.29M
14.43M
40.89%
0.43%
2.07%
Medical Devices
Surgical & Medical Instruments & Apparatus
United States
REDWOOD CITY